SEC Form 4 · accession 0001144204-16-113626
INTERCEPT PHARMACEUTICALS, INC. · ICPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Pruzanski
Officer — CEO & President · Director
Period of report
Jul 15, 2016
Accepted (ET)
Jul 19, 2016 · 9:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001270073
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 15, 2016 | M | 12,500 | $9.8223 | A | 560,066 | D | |
| Common Stock | Jul 15, 2016 | F | 7,341 | $148.73 | D | 552,725 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Common StockF2 | $9.8223 | Jul 15, 2016 | M | 12,500 | D | — | Jul 18, 2016 | Common Stock | 12,500 | 0 | D |
Explanation of responses
- F1Net share settlement of options shown on Table 2 to cover the reporting person's option exercise price and tax withholding obligations.
- F2All shares underlying this option have vested.